EMCURE PHARMACEUTICALS L Fair Value
EMCURE · Healthcare · Current price ₹1,877.5
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹360 | 20% ROE fading to 13% over ~10 yrs, on ₹261 book |
| Relative P/E | ₹1,856 | EPS × 38.1 peer-median P/E |
| Graham floor | ₹535 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,138 | Street consensus 12-month target price |
Is EMCURE PHARMACEUTICALS L undervalued?
DocStoX estimates the fair value of EMCURE PHARMACEUTICALS L at ₹1,047 per share, versus the current market price of ₹1,878. That puts the stock about -44.2% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹360), Relative P/E (₹1,856), Graham floor (₹535), Analyst target (₹2,138). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹360 (bear) to ₹1,047 (base) to ₹2,138 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on EMCURE PHARMACEUTICALS L
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.